Your immune system is not just a fighting force — it is also a meticulous cleanup operation. Dead and damaged cells must be recognized and engulfed efficiently to prevent their contents from triggering inflammation. ELMO1 (Engulfment and Cell Motility 1) is a central coordinator of this process, working within the gut epithelium and phagocytic immune cells to sense bacteria, orchestrate cytoskeletal changes needed for cell engulfment, and regulate the inflammatory signals that follow. The rs6974491 variant lies deep in ELMO1's first intron and, while it does not change the protein sequence, it acts as an expression quantitative trait locus¹¹ expression quantitative trait locus
An eQTL is a DNA variant that affects how much of a protein is made, rather than the protein's structure; the same amount of damage can be done by reducing the amount of a protein as by impairing its function — a regulatory tuning knob that alters ELMO1 expression in thymic and peripheral immune tissues.

ELMO1 operates as part of a conserved complex with DOCK180, together activating the small GTPase Rac1²² small GTPase Rac1
Rac1 is a molecular switch that triggers the cytoskeletal rearrangements needed for a cell to extend its membrane around a target and engulf it — the physical machinery of phagocytosis. This Rac1 activation drives lamellipodia formation, enabling immune cells to migrate toward signals of tissue damage and to physically engulf apoptotic cells and invading bacteria. When ELMO1 function is disrupted, cells cannot reliably complete this engulfment step — leaving cellular debris and bacteria uncleared, and triggering cascades that sustain inflammation long after the initial stimulus.

The Mechanism

rs6974491 sits at position c.78+7707 in ELMO1's first intron — approximately 7,700 nucleotides downstream of exon 1. ELMO1 is transcribed from the minus (antisense) strand³³ minus (antisense) strand
The minus strand runs in the opposite direction to the plus strand used as the genomic coordinate reference; genome files report plus-strand alleles, so G is the reference base and A is the risk allele at this position on chromosome 7, so the transcript notation is C>T while the genome file (plus-strand) reports G>A.

The A allele (plus strand) functions as an intronic regulatory variant influencing ELMO1 expression levels. An eQTL study in 42 thymic tissue samples⁴⁴ An eQTL study in 42 thymic tissue samples
Amundsen et al. examined 24 chromosomal regions carrying celiac disease SNPs for effects on thymic gene expression, identifying rs6974491-ELMO1 among nine probe-SNP pairs that replicated across both thymus and peripheral blood mononuclear cells demonstrated that rs6974491 consistently modulates ELMO1 expression in immune-relevant tissues — the thymus (where T cells are educated to distinguish self from non-self) and PBMCs (the primary immune effectors in blood).

The downstream consequence operates through two converging pathways. In gut epithelial cells, ELMO1 facilitates bacterial internalization and MCP-1 secretion⁵⁵ bacterial internalization and MCP-1 secretion
MCP-1 (monocyte chemoattractant protein 1) recruits circulating monocytes to sites of infection; its dysregulation either fails to clear pathogens or sustains excessive recruitment that drives chronic inflammation. In chronic inflammation, ELMO1 also regulates intestinal cellular senescence: ELMO1 stabilizes SIRT1 deacetylase activity, which prevents hyperacetylation of NF-κB's p65 subunit and the cellular senescence cascade that drives IBD-associated fibrosis⁶⁶ IBD-associated fibrosis. Reduced ELMO1 expression from the A allele may therefore impair both bacterial clearance and the brake on NF-κB-mediated chronic inflammation.

ELMO1 also interacts directly with NOD2⁷⁷ NOD2
NOD2 is an intracellular pattern recognition receptor that detects bacterial muramyl dipeptide — loss-of-function NOD2 mutations are among the strongest known Crohn's disease risk factors, binding through its C-terminal region to the NOD2 leucine-rich repeat domain. This physical interaction places ELMO1 in the same innate immune sensing circuit as the most established Crohn's disease risk gene.

The Evidence

The primary evidence for rs6974491's clinical relevance comes from multiple independent GWAS streams. The Dubois et al. 2010 celiac disease GWAS⁸⁸ Dubois et al. 2010 celiac disease GWAS
4,533 celiac cases and 10,750 controls; the study identified 13 new genome-wide-significant loci with ELMO1 among genes functionally relevant to the identified regions established rs6974491 as a celiac disease susceptibility signal (P < 5×10⁻⁸, OR ~1.25, 95% CI 1.16–1.36 per A allele). Notably, the study found that 52% of the identified celiac loci had variants correlated with cis-gene expression, consistent with rs6974491's eQTL mechanism.

The Mells et al. 2011 primary biliary cirrhosis GWAS⁹⁹ Mells et al. 2011 primary biliary cirrhosis GWAS
1,840 PBC cases and 5,163 UK population controls; 12 new susceptibility loci identified independently identified rs6974491 among susceptibility loci for a separate autoimmune condition — primary biliary cholangitis (PBC), an autoimmune liver disease caused by destruction of intrahepatic bile ducts. The replication of the same variant across celiac disease and PBC underscores that rs6974491 likely affects a shared mechanism of immune self-tolerance rather than organ-specific pathology.

The Parmar et al. 2012 IBD meta-analysis¹⁰¹⁰ Parmar et al. 2012 IBD meta-analysis
699 Finnish IBD patients and 2,482 controls, with Swedish UC replication; 45 genetic markers tested for celiac disease-IBD overlap found particularly strong effects in pediatric ulcerative colitis (OR 2.20, P=0.0002) and familial UC (OR 1.73, P=0.00052) — suggesting that the variant's impact on immune regulation is most visible in early-onset and familial disease forms, where genetic effects are proportionally larger.

The 2023 trans-ancestry Bayesian meta-analysis¹¹¹¹ 2023 trans-ancestry Bayesian meta-analysis
43,324 IBD cases and 57,206 controls across European, East Asian, and African American cohorts using MANTRA Bayesian analysis confirmed ELMO1 as an IBD risk locus across multiple ancestries, though the ELMO1 A allele frequency is extremely low in East Asian populations (< 0.5%), making European-ancestry findings the primary evidence base. The East Asian rarity of the A allele is notable — it makes the allele's disease associations almost exclusively a European-population story.

Practical Actions

The A allele modestly increases risk for gluten-triggered gut inflammation, IBD, and autoimmune conditions involving disrupted mucosal immunity. For GG carriers — the vast majority of the population — ELMO1 function is intact by default. For carriers of one or two A alleles, the most actionable implications concern early symptom recognition in celiac disease and IBD, and supporting the gut mucosal immune environment through specific dietary approaches.

Interactions

ELMO1 interacts directly with NOD2 (rs2066844, rs2066845, rs2066847 — common Crohn's disease variants); ELMO1 binds the NOD2 LRR domain and amplifies its bacterial sensing response. Carriers of both rs6974491-A and NOD2 loss-of-function alleles may have a compounded impairment in bacterial muramyl dipeptide sensing and clearance. Additionally, ELMO1 cooperates with DOCK180 (encoded by DOCK1) through direct physical interaction — the ELMO1/DOCK180 GEF complex is the upstream activator of Rac1, so variants affecting ELMO1 expression may compound with DOCK180 functional variants.

While rs7498665 (SH2B1 Thr484Ala) alters the structure of the SH2B1 protein, rs7359397 acts at an earlier level — it controls how much SH2B1 protein the cell makes in the first place. Located approximately 500 base pairs downstream of SH2B1 on chromosome 16, this variant sits within a CpG dinucleotide¹¹ CpG dinucleotide
A cytosine-guanine pair that is a common target for DNA methylation, which silences nearby genes when heavily methylated. The T allele creates an allele-specific methylation pattern that suppresses SH2B1 promoter activity²² suppresses SH2B1 promoter activity
When the downstream CpG region is hypermethylated, transcriptional repressors recognize the modified DNA and reduce SH2B1 mRNA output, meaning less adaptor protein available to amplify leptin and insulin receptor signals, reducing the cell's capacity to amplify both leptin and insulin receptor signals downstream of JAK2.

This variant is notably common in European populations — about 42% of Europeans carry the T allele — and has been linked specifically to NAFLD severity, insulin resistance, and differential responses to dietary interventions.

The Mechanism

SH2B1 functions as a master amplifier of JAK2 signaling. When leptin binds its receptor on hypothalamic neurons, JAK2 autophosphorylates and SH2B1 binds to phospho-JAK2 via its SH2 domain³³ SH2 domain
Src Homology 2 domain — a protein module that binds to specific phosphorylated tyrosine residues on activated kinases, dramatically increasing JAK2's catalytic activity and extending the signal through STAT3 to downstream appetite-suppressing genes. Less SH2B1 protein (due to rs7359397-driven hypermethylation) means less JAK2 amplification, blunted STAT3 phosphorylation, and reduced satiety signaling.

The CpG-SNP mechanism adds an epigenetic layer not present in coding variants: the T allele's methylation effects are potentially modifiable by dietary factors that influence one-carbon metabolism and global methylation status. This also explains the gene-diet interaction documented in intervention studies — T allele carriers respond differently to dietary composition changes that affect methyl-donor availability and insulin signaling.

The SH2B1 locus on chr16p11.2 is a dense LD block encompassing several genes (APOBR, SULT1A1, SULT1A2, TUFM); rs7359397 may partially tag effects at APOBR⁴⁴ APOBR
Apolipoprotein B receptor — involved in lipid uptake and metabolism, with its own associations with extreme obesity in fine-mapping studies. The primary phenotypic signal, however, is attributed to reduced SH2B1 expression.

The Evidence

The Mansego et al. 2015 CpG-SNP study⁵⁵ Mansego et al. 2015 CpG-SNP study
Mansego et al. SH2B1 CpG-SNP is associated with body weight reduction in obese subjects following a dietary restriction program. Annals of Nutrition and Metabolism, 2015 was the first to identify rs7359397 as a functional CpG-SNP, demonstrating that it showed the strongest association among seven obesity-related variants with weight, BMI, and truncal fat mass reduction during a caloric restriction program. The allele-specific methylation data linked the T allele to altered SH2B1 expression.

Two targeted studies from the Spanish FLiO (Fatty Liver in Obesity) cohort established the NAFLD connection. The 2020 cross-sectional study⁶⁶ 2020 cross-sectional study
Perez-Diaz-Del-Campo et al. Association of the SH2B1 rs7359397 Gene Polymorphism with Steatosis Severity in Subjects with Obesity and Non-Alcoholic Fatty Liver Disease. Nutrients, 2020 genotyped 110 obese/overweight subjects and found T allele carriers had dramatically higher rates of advanced NAFLD (69.1% vs 44.4%, p=0.006), elevated HOMA-IR (p=0.001), higher fatty liver index (OR 2.91), and nearly eight-fold greater risk of progressing to non-alcoholic steatohepatitis (RRR 7.88). The 2021 intervention follow-up⁷⁷ 2021 intervention follow-up
Perez-Diaz-Del-Campo et al. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: FLiO Study. European Journal of Nutrition, 2021 found that, despite worse baseline status, T allele carriers achieved 44.3% greater liver fat reduction (p<0.001) on the energy-restricted intervention — suggesting higher dietary sensitivity as a double-edged trait.

The insulin resistance effects extend beyond liver disease. The MAGIC consortium meta-analysis⁸⁸ MAGIC consortium meta-analysis
Fall et al. The role of obesity-related genetic loci in insulin sensitivity. Diabetic Medicine, 2012 of 37,037 participants confirmed the SH2B1 rs7359397 association with HOMA-IR (P=3.9×10⁻³). Separately, a 5,641-person young adult cohort⁹⁹ 5,641-person young adult cohort
Lange et al. Evidence for Association between SH2B1 Gene Variants and Glycated Hemoglobin in Nondiabetic European American Young Adults. Annals of Human Genetics, 2016 found significant association with HbA1c (P=9.8×10⁻⁴) largely independent of BMI, indicating a metabolic effect that operates at least partly outside the obesity pathway.

Practical Actions

Because rs7359397 acts through epigenetic regulation of SH2B1 expression, T allele carriers are particularly responsive to dietary interventions. The FLiO studies demonstrate that energy restriction produces substantially greater liver fat reduction in T allele carriers — a rare example of a genetic variant that identifies who will respond best to dietary treatment. Practically, this means T allele carriers should not assume their worse NAFLD baseline translates to worse outcomes: the data suggest the opposite under active intervention.

Liver monitoring is specifically actionable here: T allele carriers face an elevated baseline risk of NAFLD progression to NASH (RRR 7.88), and periodic liver enzyme and ultrasound monitoring can detect this progression early, when intervention is most effective.

Omega-3 fatty acid supplementation is specifically relevant for T allele carriers in NAFLD: the FLiO intervention showed T allele carriers increased omega-3 intake during the intervention and achieved superior lipidomic improvements. Higher fiber intake also tracked with better outcomes in T allele carriers.

Interactions

rs7359397 and rs7498665 are both in SH2B1 but affect the gene at different levels — rs7359397 reduces SH2B1 protein quantity (expression regulation) while rs7498665 reduces SH2B1 protein quality (structural impairment). Carriers of both T and G risk alleles simultaneously face compounded SH2B1 impairment: less protein that also functions less efficiently. The two variants are in partial but not complete LD on chr16p11.2, so they can be inherited independently and co-occur in the same individual.

SH2B1 sits upstream of LEPR (rs1137101) in the leptin signaling cascade: SH2B1 amplifies JAK2 after the leptin receptor activates it. Carrying T at rs7359397 (reduced SH2B1 expression) while also carrying a suboptimal LEPR variant compounds impairment at two sequential steps in leptin signaling.

Your muscles have two main fuels: carbohydrates (glucose stored as glycogen) and fats (fatty acids stored in adipose tissue). During moderate or prolonged exercise — and especially during fasting — muscles shift toward fat as their primary energy source. To burn long-chain fatty acids (the dominant fat in your diet and your body), those fatty acid chains must first cross into the mitochondria, the cell's power plant. That transport step requires a molecular ferry called carnitine palmitoyltransferase 2 (CPT2)¹¹ carnitine palmitoyltransferase 2 (CPT2)
A 658-amino-acid enzyme embedded in the inner mitochondrial membrane that transfers long-chain acylcarnitines across the inner membrane into the mitochondrial matrix, where β-oxidation then dismantles them into acetyl-CoA for energy. Without CPT2, long-chain fatty acids pile up outside the mitochondria, and muscle cells are forced to rely almost entirely on glycogen — which runs out quickly during sustained activity.

The p.Ser113Leu variant (c.338C>T in the CPT2 coding sequence) is the single most common mutation causing myopathic CPT II deficiency. Two copies of this variant — one from each parent — produce an enzyme that unfolds under physiological stress, leaving muscles metabolically stranded during the activities that demand fat-burning the most.

The Mechanism

The serine-to-leucine substitution at amino acid position 113 lies in a conserved region of the mature CPT2 protein. Functional studies²² Functional studies
Motlagh et al. 2016, PMID 27123472 — recombinant S113L CPT2 shows markedly increased thermolability and reduced steady-state protein levels in both fibroblasts and transfected cells show that p.Ser113Leu does not abolish enzyme synthesis — the mutant protein is made at near-normal levels — but it is substantially less stable, degrading faster than wild-type CPT2 under conditions of metabolic stress. The result is a reduced steady-state amount of functional enzyme (roughly 25–40% of normal residual activity in some assays), particularly at elevated temperatures.

This thermolability explains a hallmark feature of myopathic CPT II deficiency: febrile illness is among the most potent triggers³³ febrile illness is among the most potent triggers
Body temperatures above 38–39°C further destabilize the already marginally stable S113L protein, acutely dropping residual enzyme activity below the threshold needed to sustain muscle energy metabolism. The three classic triggers — prolonged exercise, fever, and fasting — all share a common mechanism: they increase the muscle's demand for long-chain fat oxidation at precisely the moment the S113L enzyme is least able to deliver it.

The Evidence

The S113L mutation was first identified as the common CPT2 disease allele by Taroni et al. 1993⁴⁴ Taroni et al. 1993
Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nature Genetics, 1993, who found it in 56% of mutant CPT2 alleles across 8 unrelated pedigrees with familial recurrent myoglobinuria. Subsequent population studies in European cohorts have consistently found the T allele accounting for 60–90% of CPT II deficiency alleles in Caucasians.

The overall population carrier frequency of the T allele is approximately 0.15% in gnomAD v2.1 (393/282,834 alleles globally), with a higher frequency of ~0.75% in the Ashkenazi Jewish subpopulation. Homozygotes (TT) are exceptionally rare in the population database, consistent with the clinical rarity of the condition (estimated at 1 in several hundred thousand live births for the symptomatic myopathic form).

A systematic review by Ivin et al. 2020⁵⁵ Ivin et al. 2020
Rhabdomyolysis caused by carnitine palmitoyltransferase 2 deficiency: A case report and systematic review. Journal of the Intensive Care Society, 2020 documents the cardinal clinical presentations: recurrent episodes of rhabdomyolysis (muscle fiber breakdown detectable as markedly elevated serum creatine kinase) and myoglobinuria (dark urine from released myoglobin), frequently resulting in acute kidney injury if fluid intake is insufficient during an episode. Symptoms typically begin in adolescence or early adulthood, often triggered by sustained exercise (particularly endurance activities), prolonged fasting, cold exposure, infection with fever, or combinations thereof.

For treatment, the fibrate drug bezafibrate — a PPAR-alpha/delta agonist — was shown by Bonnefont et al. 2010⁶⁶ Bonnefont et al. 2010
Long-term follow-up of bezafibrate treatment in patients with myopathic CPT2 deficiency. Clin Pharmacol Ther, 2010 to increase skeletal muscle palmitoyl-CoA oxidation rates by 39–206% in 6 patients with CPT2 deficiency (including S113L homozygotes), by upregulating residual CPT2 mRNA and enzyme expression through PPAR-mediated transcription. Patients reported increased physical activity and decreased muscular pain. Bezafibrate is not currently available in the United States (it is available in Europe and Canada) — fenofibrate is an alternative fibrate with a similar mechanism.

Practical Implications

For homozygous TT carriers, management centers on reducing dependence on long-chain fat oxidation during exercise and illness. Key strategies recommended in clinical guidelines and reviews include:

• Avoid prolonged fasting. Fasting forces muscles to rely on fatty acid oxidation. Eating regular meals with carbohydrate content is the single most effective daily precaution.
• Eat carbohydrates before sustained exercise. Pre-loading with slow-release carbohydrates (complex carbohydrates 1–2 hours before exercise) tops up muscle glycogen and delays the shift to fat oxidation during activity.
• Keep exercise sessions shorter and higher-intensity. Brief, high-intensity exercise (glycolytic by nature) is better tolerated than prolonged moderate-intensity endurance activity (which demands fat oxidation). Walking 20 minutes is less likely to trigger a crisis than jogging for 90 minutes.
• Aggressive fever management. Promptly treating febrile illness with antipyretics and ensuring adequate carbohydrate and fluid intake during infection substantially reduces crisis risk.
• Discuss fibrate therapy with your neurologist. Bezafibrate or fenofibrate may improve enzyme expression and exercise tolerance.

Heterozygous CT carriers typically have one functional CPT2 allele and maintain sufficient enzyme activity to avoid clinical disease. At least 21 heterozygous carriers have been documented with muscle CPT activity at 39–45% of normal — mildly reduced but usually asymptomatic at rest. A subset develop mild symptoms with very prolonged exertion or concurrent illness; most carriers are unaffected.

Interactions

CPT2 deficiency is a single-gene recessive disorder. Clinical severity is determined primarily by the number of T alleles and whether the second allele (in compound heterozygotes) is a null mutation or a milder missense. Compound heterozygosity for S113L (c.338C>T) plus a second rarer CPT2 mutation is the second most common genotype for adult myopathic CPT II deficiency after S113L/S113L homozygosity. The severity of compound heterozygous states depends on the residual activity of the second allele — null variants produce more severe phenotypes than missense variants.

The condition interacts with CPT1 variants (rs113994098 — CPT1B gene) at the physiological level: CPT1 and CPT2 together form the carnitine shuttle system. Variants reducing CPT1 activity from the outer mitochondrial membrane side compound with CPT2 dysfunction from the inner membrane side, though clinical interaction data for specific combined genotypes are limited.

Uterine fibroids (leiomyomata) affect up to 70% of women by age 50 and are the leading indication for hysterectomy worldwide. Their growth depends on a fundamental imbalance: fibroid smooth muscle cells proliferate but resist dying. FOXO1 — forkhead box protein O1¹¹ forkhead box protein O1
a transcription factor that drives expression of pro-apoptotic genes including BIM, PUMA, and Fas ligand — is a central regulator of that life-or-death balance. An intronic variant in FOXO1, rs7986407, has emerged from multiple genome-wide association studies as a locus influencing both uterine leiomyoma risk and the timing of natural menopause, two phenotypes that converge on estrogen exposure duration and uterine smooth muscle cell biology.

The Mechanism

Under normal conditions, FOXO1 translocates to the nucleus and transcribes genes that initiate programmed cell death — a key brake on abnormal cell accumulation. In leiomyoma cells, however, progestins (which drive fibroid growth) rapidly activate the PI3K/AKT signaling cascade²² PI3K/AKT signaling cascade
a pro-survival kinase pathway that is constitutively elevated in many tumors. Activated AKT phosphorylates FOXO1 at Ser256, causing it to be sequestered in the cytoplasm where it cannot reach its target genes. The result: pro-death signals are silenced and fibroid cells survive and accumulate. This mechanism was directly demonstrated by Hoekstra et al. (2009), who showed that blocking AKT or forcing nuclear FOXO1 entry with Psammaplysene A restored apoptosis in leiomyoma cells³³ blocking AKT or forcing nuclear FOXO1 entry with Psammaplysene A restored apoptosis in leiomyoma cells
Hoekstra AV et al. J Clin Endocrinol Metab 2009.

The rs7986407 variant is intronic and does not alter the FOXO1 protein sequence. Its functional effect likely operates through regulatory mechanisms — altered splicing efficiency, changes in intronic enhancer activity, or linkage disequilibrium with regulatory variants in the FOXO1 locus — that may modulate FOXO1 expression levels or transcript stability in uterine smooth muscle cells. The precise molecular consequence of the G allele in this tissue remains an open research question.

FOXO1 also plays a broader role in reproductive physiology: in ovarian granulosa cells, FOXO1 and its close family member FOXO3 regulate follicular development and granulosa cell apoptosis. Selective deletion of both in mice caused complete infertility⁴⁴ caused complete infertility
Liu Z et al. Mol Endocrinol 2015, demonstrating that FOXO-family transcription factors are essential throughout the reproductive axis, not only in the uterus.

The Evidence

The locus around rs7986407 has been identified in multiple large-scale GWAS efforts. The GWAS Catalog reports two fibroid associations at this variant: one with OR 1.07 (95% CI 1.04–1.10; p = 7 × 10⁻⁸; risk allele G) from studies in European-ancestry women, and a second association in a larger meta-analysis (p = 2 × 10⁻¹³; beta 0.064) where the A allele direction diverges — reflecting the complexities of phenotypic stratification across studies. A third entry in the GWAS Catalog records an association with uterine leiomyoma specifically (OR 0.93 per A allele; p = 2 × 10⁻¹⁸), consistent with a protective role of the A allele on fibroid risk.

The same A allele is associated with later age at natural menopause⁵⁵ later age at natural menopause
later menopause means longer total estrogen exposure across the reproductive lifespan at genome-wide significance (p = 4 × 10⁻¹⁹), suggesting that the A allele promotes prolonged functional ovarian activity. The relationship between these two A-allele phenotypes (later menopause and reduced fibroid risk, or context-dependent fibroid association) likely reflects the complex role of estrogen timing in uterine tissue biology.

A case-control study of 737 UF patients and 451 controls⁶⁶ case-control study of 737 UF patients and 451 controls
Ponomareva et al. 2024 found rs7986407 appearing in multiple gene-gene interaction models alongside rs547025 (SIRT3), rs2456181 (ZNF346), rs7907606 (STN1/SLK), and rs72709458 (TERT) — suggesting that the fibroid risk associated with this locus may be amplified or modified by co-occurring variants in related pathways. The SIRT3 connection is biologically plausible: sirtuin-family deacetylases directly regulate FOXO1 nuclear localization and activity, as shown by the SIRT1–FOXO1 axis in granulosa cells⁷⁷ SIRT1–FOXO1 axis in granulosa cells
miR-181a promotes SIRT1 downregulation, FOXO1 acetylation, and granulosa cell apoptosis via this axis.

Practical Actions

For women carrying two G alleles at rs7986407, the evidence may suggest a modest but biologically grounded susceptibility to uterine fibroid development, potentially acting through reduced FOXO1-mediated apoptotic surveillance in uterine smooth muscle cells. The fibroid phenotype in GG women may be modulated by factors that influence AKT pathway activity — including progestin exposure from hormonal contraception and body composition, as adipose tissue is a source of both estrogens and progestins.

Early pelvic ultrasound surveillance is the most actionable monitoring step for GG carriers. If fibroids are identified, awareness of the AKT/FOXO1 pathway biology may be relevant to treatment considerations, particularly given ongoing research into AKT-targeted fibroid therapies.

Interactions

The gene-gene interaction data from Ponomareva et al. 2024 and 2025 suggests that rs7986407 FOXO1 interacts with rs547025 SIRT3 in the context of uterine fibroid risk. SIRT3 (sirtuin 3) is a mitochondrial deacetylase with known roles in oxidative stress resistance and cellular longevity signaling. In the 2024 study, rs547025 SIRT3 showed the strongest individual protective effect against fibroids (C allele OR 0.61), while rs7986407 FOXO1 appeared repeatedly across interaction models. The biological rationale is compelling: SIRT3-family deacetylases regulate FOXO-family transcription factor activity through deacetylation, and FOXO1 acetylation status determines whether it can enter the nucleus to trigger apoptosis. A dual variant carrier — with both reduced SIRT3 protective capacity and a FOXO1 allele associated with fibroid risk — may face a convergent impairment of apoptotic regulation in uterine smooth muscle cells. Proposed compound action: SIRT3 rs547025 + FOXO1 rs7986407 — women carrying GG at rs7986407 (FOXO1, elevated fibroid risk) combined with TT at rs547025 (SIRT3, reduced protective effect) may have a compounded impairment of the SIRT3-FOXO1 apoptotic axis in uterine smooth muscle; recommended action would be earlier pelvic surveillance and monitoring of fibroid-related symptoms (heavy menstrual bleeding, pelvic pressure), plus consideration of lifestyle and dietary factors shown to support mitochondrial SIRT3 activity such as time-restricted eating and resistance exercise.

The endothelial protein C receptor (EPCR, encoded by the PROCR gene on chromosome 20) is a transmembrane glycoprotein on vascular endothelial cells that serves as the essential docking station for protein C activation¹¹ protein C activation
protein C is a vitamin K-dependent anticoagulant zymogen; when bound to EPCR, it is activated 20-fold more efficiently by the thrombin-thrombomodulin complex on the endothelial surface. Once activated, protein C (as APC — activated protein C) inactivates clotting factors Va and VIIIa, shutting down thrombin generation and protecting vessels from inappropriate clot formation. EPCR also anchors APC for cytoprotective PAR1 signaling²² cytoprotective PAR1 signaling
protease-activated receptor 1 (PAR1) triggers anti-inflammatory and endothelial barrier-stabilizing responses when activated by APC bound to EPCR — a distinct pathway from the pro-thrombotic PAR1 activation triggered by thrombin.

The rs867186 (S219G) variant substitutes glycine for serine at position 219 in the extracellular ectodomain³³ ectodomain
the portion of a transmembrane protein exposed on the cell surface, which can be proteolytically cleaved and released into circulation as a soluble fragment of EPCR. This single amino acid change dramatically alters how tightly EPCR is held at the cell surface — with consequences for both coagulation and inflammation.

The Mechanism

The Ser→Gly substitution at position 219 sits within the stalk region of EPCR adjacent to the transmembrane domain, exactly where ADAM metalloprotease-10 (ADAM10) cleaves EPCR⁴⁴ ADAM metalloprotease-10 (ADAM10) cleaves EPCR
ADAM proteases are zinc-dependent enzymes that shed ectodomains of membrane proteins; the 219Gly variant loosens the local protein structure, making the cleavage site more accessible to release soluble EPCR (sEPCR) into the bloodstream.

GG homozygotes have four-fold higher circulating sEPCR levels compared to AA homozygotes⁵⁵ GG homozygotes have four-fold higher circulating sEPCR levels compared to AA homozygotes
Ireland et al. Atherosclerosis 2005 — in vitro transfection confirmed increased basal release from cells expressing 219Gly. This has two opposing effects:

Pro-thrombotic pathway: sEPCR competitively sequesters circulating protein C away from the surface-bound EPCR that would activate it. Despite higher plasma protein C levels (because less is being activated and consumed), the functional anticoagulant response is blunted — protein C circulates but cannot dock efficiently on endothelial cells to be activated. Simultaneously, FVII and downstream coagulation activation markers (FIXpep, FXpep, prothrombin F1+2) rise proportionally with Gly allele dose⁶⁶ Gly allele dose
FVII elevated 6.9% in AG carriers and 23.4% in GG carriers vs AA, with a co-proportional rise in activated coagulation markers; Ireland et al. ATVB 2009, indicating net procoagulant shift despite the elevated protein C.

Anti-inflammatory pathway: sEPCR and APC-sEPCR complexes attenuate leukocyte-endothelial adhesion and vascular inflammation — explaining the paradoxical lower coronary artery disease risk in G allele carriers⁷⁷ paradoxical lower coronary artery disease risk in G allele carriers
Stacey et al., Nature Communications 2022 — PROCR-219Gly simultaneously reduces CAD risk through anti-inflammatory EPCR signaling while raising VTE risk through the coagulation FVII arm. This cross-phenotype pleiotropy — where the same variant decreases one vascular endpoint while increasing another — illustrates why simple "pro-thrombotic" labels can be misleading.

The Evidence

The VTE risk from rs867186 is among the most replicated associations in venous thrombosis genetics.

A HuGE meta-analysis of 37,415 cases and 84,406 non-cases across 25 studies⁸⁸ HuGE meta-analysis of 37,415 cases and 84,406 non-cases across 25 studies
Dennis et al. Blood 2012 — random-effects model, additive genetic model found each additional G allele increases VTE odds by 22% (OR 1.22, 95% CI 1.11–1.33, P < 0.001). No association was found with arterial MI.

A prospective Swedish cohort of 28,794 subjects followed through 2018⁹⁹ prospective Swedish cohort of 28,794 subjects followed through 2018
Manderstedt et al. Thrombosis and Haemostasis 2022 — Malmö Diet and Cancer Study, exome sequencing found only GG homozygosity — not AG heterozygosity — reached significance, with an adjusted HR of 1.5 (95% CI 1.1–2.0). This recessive-at-the-clinical-threshold pattern aligns with the dose-response in coagulation markers.

A subsequent meta-analysis of 5,768 cases and 30,017 controls¹⁰¹⁰ meta-analysis of 5,768 cases and 30,017 controls
Pituk et al. Front Cardiovasc Med 2023 — pooled analysis including their own Hungarian case-control study quantified genotype-specific risk more precisely: dominant model OR 1.27 (95% CI 1.11–1.46), recessive model OR 1.60 (95% CI 1.26–2.04), and GG versus AA OR 1.64 (95% CI 1.28–2.09). The same study found a non-significant trend toward higher VTE recurrence risk (OR 1.72, 95% CI 0.95–3.13, p = 0.075) in G carriers — a signal that may be meaningful for anticoagulation duration decisions.

At the genome-wide level, Thibord et al. Circulation 2022¹¹¹¹ Thibord et al. Circulation 2022
cross-ancestry GWAS of up to 81,669 VTE cases from 30 studies in European, African, and Hispanic populations — confirmed PROCR as an independent VTE locus among 135 significant signals and the Ghouse et al. Nature Genetics 2023¹²¹² Ghouse et al. Nature Genetics 2023
genome-wide meta-analysis of 81,190 cases and 1,419,671 controls — 93 risk loci, with PROCR among replication-confirmed signals both confirmed PROCR as an independent VTE risk locus in the largest genetic studies of venous thromboembolism conducted to date.

Practical Actions

For AG heterozygotes (the most common risk genotype at ~17.5% prevalence), the absolute risk increase is modest and typically does not alter standard clinical management. The key implication is awareness: recognizing an elevated baseline risk enables informed decisions around high-risk exposures such as prolonged immobility, surgery, or estrogen-containing contraceptives.

For GG homozygotes (~1% prevalence), the risk increment is clinically more meaningful (HR ~1.5 for incident VTE, OR ~1.64 in meta-analysis). This genotype warrants factoring into thrombotic risk stratification, particularly after a first unprovoked VTE when deciding on anticoagulation duration. PROCR S219G does not carry standalone indication for prophylactic anticoagulation, but it strengthens the case for extended therapy in ambiguous clinical scenarios.

The anti-inflammatory pleiotropic effect (lower CAD risk) does not require intervention — it is a passive benefit of the shedding mechanism.

Interactions

Factor V Leiden (rs6025) and prothrombin G20210A (rs1799963) are the strongest known inherited thrombophilia variants. Combining rs867186 with either of these creates a substantially higher cumulative VTE risk than any single variant alone, as these operate through independent mechanisms — FVII/PROCR pathway versus thrombin generation and fibrin deposition. Any carrier of rs867186 GG who also carries factor V Leiden or prothrombin mutation should be evaluated by a hematologist for thrombophilia risk stratification.

A second functional PROCR variant, Arg113Cys (rs146420040), was identified in the same Malmö cohort study and confers independent VTE risk (HR 1.3). The combination of both PROCR variants in the same individual has not been formally studied but would be expected to compound risk further.

IL-13¹¹ IL-13
Interleukin-13, a 12.5 kDa cytokine secreted primarily by activated Th2 CD4+ T cells, mast cells, and basophils is one of two master regulators of allergic disease — the other being IL-4. While IL-4 orchestrates the initial Th2 commitment and IgE class switching, IL-13 executes the downstream tissue effects: airway smooth muscle contraction, mucus hypersecretion by goblet cells, subepithelial fibrosis, and IgE amplification. Together they form the axis that makes allergic asthma, atopic eczema, and allergic rhinitis chronic rather than self-limiting.

The rs1800925 variant, also written as IL13 -1112C>T, sits in the IL13 gene promoter region on chromosome 5q31 — not in the protein-coding sequence, but upstream of it, in the DNA elements that control when and how much IL-13 gets made. The C allele is the reference and common form. The T allele, carried by about 20% of Europeans and 38% of Africans, silently rewires a key regulatory node in Th2 immune cells.

The Mechanism

The -1112 region of the IL13 promoter normally contains a STAT6 binding motif²² STAT6 binding motif
Signal transducer and activator of transcription 6 — the transcription factor activated downstream of IL-4 and IL-13 receptor signaling, which feeds back to suppress further IL-13 transcription. When STAT6 binds this site in Th2 cells, it partially represses IL13 gene expression, creating a negative feedback brake.

The T allele change at position -1112 disrupts the STAT6 binding motif and simultaneously creates a Yin-Yang 1 (YY1)³³ Yin-Yang 1 (YY1)
A zinc-finger transcription factor with context-dependent activating or repressing functions, named for its ability to act as both activator and repressor depending on cofactors present binding site that overlaps the STAT6 motif. YY1 then competes with STAT6 for binding to this locus. In polarized Th2 cells — exactly the context of active allergic disease — this competition tips in favor of YY1, attenuating STAT6-mediated repression and selectively boosting IL13 transcription⁴⁴ attenuating STAT6-mediated repression and selectively boosting IL13 transcription. The effect is Th2-selective: the same variant has opposing effects in non-polarized T cells, where the nuclear milieu favors STAT6 binding.

The consequence is increased IL-13 production at the tissue level in allergic individuals, which drives goblet cell hyperplasia and mucus secretion in airways, enhances IgE production by B cells (via IL-4Rα/IL-13Rα1 type II receptor), reduces airway responsiveness by altering smooth muscle physiology, and promotes subepithelial fibrosis in chronic disease. Individuals homozygous for the T allele produce measurably more IL-13 from activated Th2 cells.

The Evidence

The -1112C>T functional mechanism was established in 2006 by Cameron et al., who used ChIP assays and EMSA in primary human Th2 cells to show allele-specific STAT6 and YY1 binding at the -1112 locus and confirmed increased IL-13 secretion in TT homozygous subjects⁵⁵ Cameron et al., who used ChIP assays and EMSA in primary human Th2 cells to show allele-specific STAT6 and YY1 binding at the -1112 locus and confirmed increased IL-13 secretion in TT homozygous subjects. This remains the definitive mechanistic study.

Clinical associations span asthma, COPD, and atopic disease. A 2023 meta-analysis (Gaceja et al.) of 11 studies including 2,895 asthma cases and 2,914 controls⁶⁶ 2023 meta-analysis (Gaceja et al.) of 11 studies including 2,895 asthma cases and 2,914 controls found the TT genotype significantly associated with allergic asthma risk in Asian populations under the recessive model (OR 1.48, 95% CI 1.14–1.93) and codominant model (TT vs CC: OR 1.66, 95% CI 1.27–2.17). West Asian populations (Iranian and Saudi) showed the strongest effect (OR 2.17).

For lung disease, a 2017 meta-analysis of 9 studies (Liao et al., 3,077 participants) found the T allele associated with COPD risk overall⁷⁷ 2017 meta-analysis of 9 studies (Liao et al., 3,077 participants) found the T allele associated with COPD risk overall with OR 1.57 (95% CI 1.21–2.04), driven by both Asian (OR 1.88) and Caucasian (OR 1.30) subgroups.

A particularly important pharmacogenomic finding emerged from the CAMP childhood asthma study: Hunninghake et al. (2007) found that the T allele was associated with increased asthma exacerbations specifically in children on inhaled corticosteroids⁸⁸ Hunninghake et al. (2007) found that the T allele was associated with increased asthma exacerbations specifically in children on inhaled corticosteroids (P=0.02) — the first report of a potential negative gene-ICS interaction for this locus. This suggests T carriers may have attenuated corticosteroid benefit from standard inhaled therapy.

The variant also interacts with environmental exposures. Choudhry et al. (2008) demonstrated that IL13 rs1800925 genotype modifies the effect of prenatal tobacco smoke exposure on persistent wheeze in childhood⁹⁹ Choudhry et al. (2008) demonstrated that IL13 rs1800925 genotype modifies the effect of prenatal tobacco smoke exposure on persistent wheeze in childhood, and the NSHD cohort found evidence for smoking-rs1800925 interaction on allergy risk across the life course¹⁰¹⁰ evidence for smoking-rs1800925 interaction on allergy risk across the life course. T carriers who smoke face compounded risk beyond either factor alone.

Practical Actions

For T allele carriers — particularly those with existing atopic disease — the key intervention targets are the IL-4/IL-13 Th2 axis and mucus pathway, alongside monitoring of corticosteroid effectiveness. Since IL-13 itself is now a validated biologic drug target (tralokinumab, lebrikizumab), the biology underlying this SNP is clinically actionable at the therapeutic level.

Total and specific IgE measurement quantifies the downstream consequence of enhanced IL-13 signaling and helps identify the specific allergens being amplified by your Th2 bias. Monitoring IgE trends over time provides objective feedback on whether dietary, supplement, or medication interventions are effective.

For CT carriers with asthma managed on inhaled corticosteroids, the possible ICS-rs1800925 interaction warrants attention to whether current treatment is achieving expected control. If asthma remains poorly controlled despite standard ICS therapy, discussing add-on therapies (LABA, leukotriene modifiers, or biologic options) with a specialist is appropriate.

Interactions

The most important interaction partner is [rs20541 | IL13 R130Q coding variant — the Q130 minor allele (A) directly increases IL-13 protein activity], which is in moderate LD with rs1800925. The -1112T allele increases the amount of IL-13 made; the Q130/rs20541-A allele increases the activity of the protein made. Carrying risk alleles at both loci compounds IL-13 pathway amplification through independent mechanisms — the TA haplotype (rs1800925-T + rs20541-A) is consistently the highest-risk haplotype for atopic disease.

The [rs1801275 | IL4R Q576R — gain-of-function variant in the shared IL-4/IL-13 receptor alpha chain] from the same Th2 pathway amplifies signaling from both IL-4 and IL-13. A carrier of rs1800925-T (more IL-13 produced) with rs1801275-G (more IL-13 signal transduced) faces dual amplification of the same pathway.

Smoking exposure warrants particular attention: multiple studies show that tobacco smoke interacts with rs1800925 genotype to amplify wheeze and allergy risk beyond what either factor alone predicts, likely because smoke-induced airway inflammation further activates Th2 cells that are already primed to over-produce IL-13.

N-acetyltransferase 2 (NAT2) is a Phase II ¹¹ Phase II detoxification conjugates reactive intermediates from Phase I with small molecules to make them water-soluble and excretable detoxification enzyme that adds an acetyl group to aromatic amines and hydrazines, making them water-soluble so your body can excrete them. These substrates include environmental carcinogens from cigarette smoke, heterocyclic amines ²² Heterocyclic amines are carcinogenic compounds formed when meat is cooked at high temperatures, especially charring or grilling from cooked meat, and medications like isoniazid (tuberculosis treatment) and sulfasalazine.

The Mechanism

The I114T variant (rs1801280) changes isoleucine to threonine at position 114 of the NAT2 protein. The C allele (Thr) destabilizes the enzyme, leading to faster degradation and lower acetylation capacity. This is one of the most common "slow acetylator" alleles in European populations, characterizing the NAT2*5B haplotype. The C allele frequency is remarkably high in Europeans (~44%) but very rare in East Asians (~3%).

Slow vs. Rapid Acetylators

NAT2 acetylator status is determined by the combination of multiple variants (rs1801280, rs1799930, rs1208). You need two slow alleles (one from each parent) to be a slow acetylator. About 50-60% of Europeans are slow acetylators ³³ This high frequency suggests slow acetylation may have been advantageous in certain ancestral environments due to the high frequency of these variants, compared to only 10-20% of East Asians.

Clinical Significance

Slow acetylators have increased risk of bladder cancer from occupational exposure to aromatic amines. A major meta-analysis⁴⁴ major meta-analysis
Garcia-Closas M et al. NAT2 slow acetylation and bladder cancer risk. Lancet, 2005 found an overall OR of 1.4 (95% CI 1.2-1.7) for bladder cancer in slow acetylators, with stronger effects in cigarette smokers. Slow acetylators also require dose adjustments for isoniazid and are more prone to drug-induced lupus from certain medications. However, slow acetylation may actually be protective in some contexts - rapid acetylators have higher colorectal cancer risk from heterocyclic amines in well-done meat.

Practical Advice

If you are a slow acetylator: minimize exposure to cigarette smoke (active and secondhand), moderate consumption of heavily charred or grilled meats, and inform your doctor of your acetylator status if prescribed isoniazid or other NAT2 substrate medications.

The TMPRSS3 gene encodes a type II transmembrane serine protease¹¹ type II transmembrane serine protease
Anchored to the cell membrane with its catalytic serine protease domain facing the extracellular space; expressed in cochlear inner and outer hair cells, spiral ganglion neurons, and the stria vascularis essential for the survival of cochlear hair cells at the onset of hearing. Of the more than 87 documented TMPRSS3 pathogenic variants, the p.Ala306Thr missense change caused by c.916G>A is the single most common allele detected across all populations²² the p.Ala306Thr missense change caused by c.916G>A is the single most common allele detected across all populations
Identified in Korean, Chinese, Dutch, and German families; classified as a Korean and Chinese founder mutation; the most frequently reported mutation in published TMPRSS3 literature — making it a high-priority target for both clinical recognition and emerging gene therapy approaches.

This variant is catalogued in ClinVar (variation 46131) as Pathogenic/Likely pathogenic for autosomal recessive nonsyndromic hearing loss 8 (DFNB8), with 17 submitting laboratories providing criteria-based evidence, and no conflicting classifications.

The Mechanism

TMPRSS3 is synthesized as an inactive single-chain precursor (zymogen) that must undergo autocatalytic self-cleavage³³ autocatalytic self-cleavage
The serine protease domain cleaves itself at a specific arginine residue to release the active two-chain form; TMPRSS3 is one of the few serine proteases that activates itself rather than relying on an upstream activator to become active. This active form then contributes to epithelial sodium channel (ENaC) activation in cochlear hair cells and, through as-yet incompletely characterized pathways, supports hair cell survival.

The p.Ala306Thr substitution places a threonine — a bulkier, polar amino acid — at position 306 within the serine protease catalytic domain⁴⁴ serine protease catalytic domain
The catalytic triad of serine proteases (His, Asp, Ser) requires precise spatial arrangement for activity; Ala306 sits adjacent to the active-site residue Asp304, and any perturbation of local geometry can disrupt substrate binding and catalysis. Molecular modeling shows that wild-type Ala306 forms two salt bridges with Thr254, while mutant Thr306 forms an additional unnatural salt bridge with Val291 — a structural perturbation predicted to directly impair catalytic function. Crucially, p.Ala306Thr does not abolish TMPRSS3 autocatalytic processing the way the R216L null allele does; instead it reduces activity, making it a hypomorphic variant⁵⁵ hypomorphic variant
A hypomorph retains partial protein function, as opposed to an amorph (null). TMPRSS3 A306T knockin mice develop delayed-onset progressive hearing loss rather than the complete congenital deafness seen with biallelic null alleles, confirming residual function. The residual activity is insufficient for long-term cochlear hair cell survival but supports initial postnatal hearing — explaining the postlingual, progressive clinical phenotype.

The Evidence

Founder mutation status is established for multiple populations. In the Chinese population⁶⁶ In the Chinese population
Zheng et al. 2017, screening 151 ARNSHL families lacking GJB2/SLC26A4 mutations; TMPRSS3 accounted for 4.6% of cases; c.916G>A was found in 2% of all alleles; haplotype analysis showed linkage disequilibrium across 4/6 families supporting a common ancestor, this allele is clearly a founder mutation. In Korea⁷⁷ In Korea
Carrier rate among Korean postlingual hearing loss patients with TMPRSS3 mutations was 8.3%; p.A306T is the dominant founder allele with haplotype evidence, the same conclusion holds. It has also been independently found in Dutch and German families.

Genotype-phenotype correlations reveal a pattern with clear clinical relevance. Weegerink et al. 2011 in Dutch DFNB8/10 families⁸⁸ Weegerink et al. 2011 in Dutch DFNB8/10 families
8 families studied; the study established the principle that TMPRSS3 allele combinations predict phenotype: two severe alleles → DFNB10 (prelingual profound), one severe + one mild → DFNB8 (postlingual progressive) established p.Ala306Thr as a severe allele. When p.Ala306Thr pairs with a truncating or null allele (such as rs727503493 c.208delC frameshift or rs137853000 R216L), the result is typically prelingual profound hearing loss (DFNB10 phenotype). When it pairs with a mild missense allele, postlingual progressive loss (DFNB8 phenotype) results. This distinction has major clinical implications: DFNB8 patients retain speech for years to decades, while DFNB10 patients require intervention from infancy.

The A306T mouse model provides mechanistic confirmation. Du et al. 2023⁹⁹ Du et al. 2023
Molecular Therapy; CRISPR-Cas9 knockin of the human c.916G>A allele into CBA/CaJ mice created Tmprss3A306T/A306T homozygous animals that develop late-onset progressive HL beginning after 10.5 months, with average threshold elevation of ~26 dB by 22.5 months — exactly recapitulating the human DFNB8 pattern created and validated an A306T knockin mouse model. A single AAV2-hTMPRSS3 injection into 18.5-month-old mice (equivalent to a middle-aged adult human) restored hearing thresholds to wild-type levels, preserved outer hair cell survival, and tripled spiral ganglion neuron survival — making this the first successful gene therapy demonstration in an aged mouse model of hereditary deafness.

Cochlear implant outcomes are favorable. Colbert et al. 2024¹⁰¹⁰ Colbert et al. 2024
127 patients, 16 centers, 6 countries; mean word recognition score 76%; age at implantation is the dominant outcome predictor — each year of delay associated with measurable speech perception decrement confirmed excellent outcomes across the TMPRSS3 patient population. Individual published cases of A306T compound heterozygotes have achieved 65–91% phoneme scores with cochlear implants.

Practical Implications

For confirmed biallelic A306T carriers (TT), or compound heterozygotes carrying one A306T allele and one other pathogenic TMPRSS3 allele, the clinical priority is early audiological characterization, progressive monitoring, and timely cochlear implant referral. The progressive nature of DFNB8 means that TMPRSS3-related hearing loss often presents in childhood with high-frequency loss that progresses over years to decades — a pattern that may be initially confused with noise-induced or idiopathic progressive loss. Genetic diagnosis changes the trajectory by enabling intervention planning.

Looking forward, the AAV-TMPRSS3 gene therapy approach validated in the A306T mouse model represents a genuine therapeutic pipeline specifically targeted to this allele. Carriers with this mutation should be tracked in TMPRSS3 natural history registries that will feed into gene therapy trials.

Interactions

The dominant interaction is compound heterozygosity with other TMPRSS3 pathogenic alleles. Because p.Ala306Thr is a severe (not null) allele:

• A306T + null allele (rs137853000 R216L, rs727503493 c.208delC): Expected DFNB10 — prelingual profound deafness. The null allele contributes no function; A306T's residual activity is insufficient to rescue the phenotype to postlingual onset.
• A306T + mild missense (p.Ala426Thr, p.Ala138Glu, p.Thr248Met, or intronic variants): Expected DFNB8 — postlingual progressive hearing loss, typically onset in childhood to early adulthood, ski-slope audiogram.
• Homozygous A306T/A306T: Also causes DFNB8-type progressive HL; the mouse model Tmprss3A306T/A306T confirms delayed-onset progressive loss, not congenital profound deafness.

The severity-based prediction framework is clinically actionable: when a TMPRSS3 evaluation returns A306T on one allele, comprehensive sequencing of the second allele determines whether the patient faces DFNB8 (mild + mild = postlingual) or DFNB10 (mild + severe = prelingual profound) outcome. See also rs137853000 (R216L, complete null allele) and rs727503493 (c.208delC frameshift) for the other shipped TMPRSS3 pathogenic alleles.

A possible digenic interaction with GJB2 (connexin 26)¹¹¹¹ GJB2 (connexin 26)
GJB2 encodes the gap junction protein connexin 26, the most common cause of genetic hearing loss in most populations; initial reports suggested TMPRSS3/GJB2 digenic cases, but larger series have not confirmed this as a distinct entity has been explored but is not established. When a single TMPRSS3 pathogenic allele is found in a hearing-loss patient, comprehensive deafness gene panel testing including GJB2 should be performed before concluding the patient is a carrier rather than a compound heterozygote.

Inside every pancreatic beta cell, a single enzyme acts as the body's glucose sensor: glucokinase¹¹ glucokinase
Also called hexokinase IV; the rate-limiting enzyme for glucose phosphorylation in beta cells and hepatocytes. By catalyzing the first committed step of glycolysis — converting glucose to glucose-6-phosphate — glucokinase determines the blood glucose concentration at which insulin secretion is triggered. The Ala378Val substitution encoded by this variant disrupts that sensor, shifting the entire glucose threshold for insulin release upward. One copy of this variant (heterozygous state) causes GCK-MODY²² GCK-MODY
Maturity-onset diabetes of the young type 2; also called MODY2. Characterized by lifelong mild fasting hyperglycemia from birth, autosomal dominant inheritance, and low rates of vascular complications, the most common and benign form of monogenic diabetes.

The Mechanism

Alanine 378 sits within the catalytic core of glucokinase, close to the glucose binding site. The substitution of the small, nonpolar alanine with the bulkier valine residue impairs the enzyme's conformational flexibility and reduces its glucose-binding affinity and catalytic rate. In the homozygous state, the Ala378Val variant essentially abolishes glucokinase activity — enzyme kinetics studies show only 0.2% of wild-type activity when both alleles carry this substitution — ³³ Njølstad et al. 2003 — homozygous Ala378Val: activity index 0.2% of wild-type, causing permanent neonatal diabetes with intrauterine growth retardation (Diabetes, PMID 14578306) leading to near-complete glucokinase deficiency and permanent insulin-dependent diabetes from birth.

In the heterozygous state, one functional copy of glucokinase remains. The beta cell still senses glucose, but the set-point is shifted: higher blood glucose concentrations are required before significant insulin secretion is triggered. This results in a stable, mild elevation of fasting blood glucose (typically 5.5–8.0 mmol/L, or 99–144 mg/dL) that is present from birth and does not progressively worsen. The condition is lifelong but largely stable.

The Evidence

GCK-MODY is one of the best-characterized forms of monogenic diabetes. The Osbak et al. 2009 review⁴⁴ Osbak et al. 2009 review
Update on mutations in glucokinase (GCK) which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Human Mutation, 2009 catalogued 620 inactivating mutations across 1,441 families, establishing that heterozygous inactivating GCK mutations uniformly produce MODY2 while homozygous mutations cause permanent neonatal diabetes — a dose-response relationship that reflects the gene's haplosufficiency threshold.

Crucially, long-term follow-up data show that the chronic mild hyperglycemia of heterozygous GCK-MODY does not cause the vascular complications typically seen in type 2 diabetes. Pruhova et al. (2013) found no increase in carotid intima-media thickness in GCK-MODY patients compared with normoglycemic controls, despite decades of elevated fasting glucose. ⁵⁵ Pruhova et al. 2013 — chronic mild hyperglycemia in GCK-MODY does not increase carotid intima-media thickness vs controls, confirming benign vascular course (PMID 24101925) The Ala378Val variant was specifically identified in multiple unrelated individuals with non-autoimmune, non-insulin-deficient monogenic diabetes and meets multiple ACMG/AMP pathogenicity criteria (PP1_Strong, PS4, PM5, PP2, PP3) as reviewed by the ClinGen Monogenic Diabetes Expert Panel in 2023.

Practical Actions

For heterozygous carriers, the clinical implication is that this is not type 1 or type 2 diabetes — it is a distinct condition with a fundamentally different prognosis. Insulin and oral hypoglycemics are generally not recommended for GCK-MODY in the non-pregnant state, as lowering glucose below the genetically elevated set-point can cause hypoglycemia without meaningful long-term benefit. The exception is pregnancy: if the fetus has not inherited the GCK mutation, maternal treatment may be warranted to avoid fetal overgrowth.

Genetic testing of first-degree relatives is important: GCK-MODY is autosomal dominant, so each parent, sibling, and child of a carrier has a 50% probability of carrying the same variant.

Interactions

The fasting glucose set-point in GCK-MODY is independent of, and additive with, common GWAS variants in the same pathway — including the GCK regulatory region (rs1799884) and the glucokinase regulatory protein gene GCKR (rs1260326). These common variants modulate fasting glucose at a population level by a few tenths of a mmol/L, while the Ala378Val pathogenic variant raises the set-point by approximately 1–2 mmol/L — orders of magnitude larger than any common variant effect. Compound heterozygosity with other GCK inactivating mutations, though theoretically possible, is extremely rare; homozygosity for Ala378Val produces the severe neonatal phenotype described by Njølstad et al.

CYP3A4 is the most versatile drug-metabolizing enzyme in the human body, responsible for processing approximately 50% of all prescription medications — from transplant immunosuppressants and statins to psychiatric drugs and opioids. The *1G variant (rs2242480) sits in intron 10 of CYP3A4, a seemingly innocuous location. Yet its effects on enzyme expression are clinically meaningful enough to appear on transplant pharmacogenomics panels and to influence tacrolimus and sirolimus trough concentrations by two- to three-fold in transplant patients.

Unlike the well-characterized *22 splice variant (rs35599367), *1G does not disrupt a splicing factor binding site. Instead, its mechanism runs through an indirect regulatory pathway involving a long noncoding RNA.

The Mechanism

Collins and Wang (2022)¹¹ Collins and Wang (2022)
Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the CYP3A4*1G association identified AC069294.1, an antisense [long noncoding RNA | lncRNA: a class of RNA molecules longer than 200 nucleotides that do not code for protein but regulate gene expression] as a negative regulator of both CYP3A4 and CYP3A5. Knockdown of this lncRNA increased CYP3A4 mRNA approximately 3-fold; overexpression reduced it by 89%. The rs2242480 T allele (*1G) sits approximately 2.7 kb upstream of the lncRNA gene and is associated with 1.26-fold increased lncRNA expression (P<0.0001). Downstream of this, *1G carriers show 31% lower CYP3A4 expression (P=0.008) and 39% lower CYP3A5 expression (P=0.004). Yang et al. (2023)²² Yang et al. (2023)
CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells confirmed this in engineered cell lines, showing allele-dependent reduction in both mRNA and protein, with decreased tacrolimus metabolism particularly in heterozygous GA (plus-strand: CT) cells.

On the chromosome, CYP3A4 lies on the minus strand. The variant is described in coding-strand notation as c.1026+12G>A, but in genome files (which always use the plus strand), it reads as a C>T change at chromosome 7 position 99,763,842 (GRCh38). The reference allele C corresponds to the wild-type *1 haplotype; the alternate T allele defines *1G.

The Evidence

The most clinically relevant evidence comes from transplant medicine. Miura et al. (2011)³³ Miura et al. (2011)
Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients followed 136 renal transplant recipients and found that CYP3A4*1G carriers had significantly lower dose-adjusted tacrolimus AUC and trough concentrations — an effect approximately half the magnitude of CYP3A5 expresser status but independently significant (P=0.018). Dong et al. (2022)⁴⁴ Dong et al. (2022)
CYP3A7, CYP3A4, and CYP3A5 polymorphisms in recipients influence tacrolimus concentrations after liver transplantation found CC recipients had approximately twice the dose-adjusted trough concentration as TC/TT carriers (189.8 vs 99.7 ng/mL per mg/kg/day, P<0.001) in 138 liver transplant patients. Uesugi et al. (2013)⁵⁵ Uesugi et al. (2013)
CYP3A4*1G polymorphism and tacrolimus in liver transplant patients observed similar direction effects in a 410-patient Japanese cohort, with CYP3A4*1/*1 donors yielding 37% higher concentration/dose ratios than *1/*1G donors in the first week post-transplant.

For sirolimus, a 2020 study of 69 renal transplant recipients⁶⁶ a 2020 study of 69 renal transplant recipients
CYP3A4 rs2242480 associated with sirolimus trough concentrations found CC carriers achieved 533 vs 157–143 (ng/mL)/mg/kg trough concentrations compared to TC and TT carriers respectively (P<0.0001) — a greater than three-fold difference that could mean the difference between subtherapeutic and supratherapeutic exposure.

Beyond transplant medicine, a meta-analysis of 18 studies encompassing 2,546 epilepsy patients⁷⁷ a meta-analysis of 18 studies encompassing 2,546 epilepsy patients
Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism found the *1G allele (G in coding-strand notation, T in plus-strand) markedly reduced plasma carbamazepine concentrations. For psychiatric drugs, Dai et al. (2026)⁸⁸ Dai et al. (2026)
CYP3A4 rs2242480 and lurasidone in Chinese bipolar depression modeled 133 patients and found CC carriers had 25% lower lurasidone clearance than TT carriers (330 vs 441 L/h), translating to meaningfully higher drug exposure at equivalent doses.

Practical Actions

The primary clinical application of CYP3A4*1G genotyping is in transplant medicine, where tacrolimus and sirolimus have narrow therapeutic windows — the difference between rejection and toxicity. CC homozygotes (the wild-type) metabolize CYP3A4 substrates efficiently and require standard doses. CT heterozygotes (*1/*1G) have moderately reduced enzyme activity; for tacrolimus and sirolimus, starting doses may need upward adjustment or more frequent monitoring to reach target trough levels. TT homozygotes (*1G/*1G) have the greatest reduction in CYP3A4 expression and the lowest drug clearance; they may achieve target tacrolimus/sirolimus levels at lower doses than standard, reducing nephrotoxicity risk.

For CYP3A4-metabolized statins (atorvastatin, simvastatin, lovastatin), TT carriers accumulate higher statin levels and may be at increased risk of myopathy at standard doses. The statin evidence is more limited than for immunosuppressants, but the directionality is consistent.

Interactions

CYP3A4*1G and CYP3A4*22 (rs35599367) are independent variants in the same gene. A patient carrying both the *1G and *22 alleles would be expected to have compounded reductions in CYP3A4 activity. Similarly, CYP3A5 expresser status (rs776746 *1/*3) strongly modifies the *1G effect — Miura et al.⁹⁹ Miura et al.
Tacrolimus PKs in renal transplant showed the lowest dose-adjusted AUC occurred in patients who were both *1G carriers and CYP3A5 expressers, because CYP3A5 expression itself boosts metabolic capacity that the *1G variant then partially suppresses. For a complete picture of CYP3A metabolizer phenotype, both rs2242480 (*1G) and rs776746 (CYP3A5*3) should be considered together.